Takashita *et al* (2013) Characterization of neuraminidase inhibitor‐resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post‐pandemic periods in Japan. Influenza and Other Respiratory Viruses 7(6), 1390--1399.23745712

Introduction {#irv12132-sec-0005}
============

During the 2007--2008 influenza season, oseltamivir‐resistant former seasonal A(H1N1) viruses emerged in Europe[1](#irv12132-bib-0001){ref-type="ref"} and became the majority of A(H1N1) viruses within a year. These oseltamivir‐resistant A(H1N1) viruses possessed a mutation causing a histidine‐to‐tyrosine substitution at amino acid position 275 (N1 numbering, H275Y) in the neuraminidase (NA) protein. The NA of these viruses had a slightly higher activity and affinity for the substrate than that from previously circulating sensitive viruses.[2](#irv12132-bib-0002){ref-type="ref"} Furthermore, some potentially permissive substitutions in the NA and the hemagglutinin (HA) protein in addition to the H275Y substitution were reported,[3](#irv12132-bib-0003){ref-type="ref"}, [4](#irv12132-bib-0004){ref-type="ref"} so that oseltamivir‐resistant A(H1N1) viruses may acquire the capacity for efficient human‐to‐human transmission. The global spread of oseltamivir‐resistant A(H1N1) viruses was obliged to change the chemotherapeutic strategy and limited the therapeutic options for influenza. Consequently, the worldwide monitoring of antiviral‐resistant viruses is important for therapeutic and public health measures. In particular, in Japan, four NA inhibitors, oseltamivir, peramivir, zanamivir, and laninamivir, are approved for chemotherapy against influenza and are prescribed with the highest frequency in the world.[5](#irv12132-bib-0005){ref-type="ref"} Therefore, Japan is at high risk of the emergence of NA inhibitor‐resistant viruses. Because updated surveillance information on antiviral‐resistant viruses from Japan is desired, year‐round surveillance for influenza antiviral resistance has been conducted through the National Institute of Infectious Diseases, in cooperation with 74 local public health institutes in Japan.

We have reported oseltamivir‐resistant A(H1N1)pdm09 viruses through a preliminary surveillance of NA inhibitor‐resistant viruses during 2009--2010.[6](#irv12132-bib-0006){ref-type="ref"} In the present study, we screened more than 12 000 A(H1N1)pdm09 viruses isolated during four influenza seasons, from the 2008--2009 season through the 2011--2012 season, to monitor NA inhibitor‐resistant viruses, and we detected 157 (1·3%) H275Y mutant viruses exhibiting cross‐resistance to oseltamivir and peramivir. We describe here the virological characteristics of the oseltamivir‐ and peramivir‐resistant A(H1N1)pdm09 viruses, the prescription history of patients infected with these resistant viruses and clusters of resistant virus infection.

Methods {#irv12132-sec-0006}
=======

Viruses {#irv12132-sec-0007}
-------

Clinical specimens and the corresponding patient records were collected in 500 sentinel hospitals consisting of pediatrics and internal medicine between May 2009 and August 2012 as part of the National Epidemiological Surveillance of Infectious Diseases in Japan. Most specimens were collected at the first medical examination. Influenza A(H1N1)pdm09 viruses were isolated from the specimens in 74 local public health institutes using Madin--Darby canine kidney (MDCK) or human colon carcinoma (Caco‐2) cells. About three isolates per week were used for allelic discrimination assay and/or partial NA gene sequencing in the local public health institutes. Approximately 5--10% of total isolates were propagated in MDCK cells and used for NA inhibition assay and/or full‐length NA and HA gene sequencing in the National Institute of Infectious Diseases.

Allelic discrimination assay {#irv12132-sec-0008}
----------------------------

To detect the H275Y substitution in NA, the allelic discrimination assay was performed as previously described.[7](#irv12132-bib-0007){ref-type="ref"} Briefly, supernatants of A(H1N1)pdm09 virus‐infected cells were directly added to the one‐step duplex RT‐PCR mixture without RNA purification, and the reaction was performed using the QuantiTect Virus kit (Qiagen, Dusseldorf, Germany). Fluorescent signals were collected during the annealing and extension steps, and amplification data and endpoint data were analyzed. Detection sensitivity of the allelic discrimination assay is 7·5 copies/reaction[7](#irv12132-bib-0007){ref-type="ref"}, and the assay detects a mixed population of H275Y mutant viruses and 275H wild‐type viruses. We considered all mixed population as H275Y.

Sequence analysis {#irv12132-sec-0009}
-----------------

Viral RNA was prepared using the QIAamp Viral RNA kit (Qiagen). To screen for the H275Y substitution in NA, the partial NA gene between 676 and 1,111 (from the start codon) was amplified from the viral RNA as previously described.[7](#irv12132-bib-0007){ref-type="ref"} The full‐length NA gene was amplified from viral RNA using a plus‐sense primer N1‐F1 and a minus‐sense primer N1‐R1 (Table [1](#irv12132-tbl-0001){ref-type="table-wrap"}). The HA1 domain of the HA gene was amplified using a plus‐sense primer H1HA1‐BEGIN and a minus‐sense primer H1‐1106‐1087R (Table [1](#irv12132-tbl-0001){ref-type="table-wrap"}). Nucleotide sequences were determined using the BigDye Terminator v3·1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA) with Applied Biosystems 3730 DNA Analyzer. The sequencing primers are shown in Table [1](#irv12132-tbl-0001){ref-type="table-wrap"}. DNA sequence assembly and analysis were performed using Sequencher 4·9 software (Gene Codes Corporation, Ann Arbor, MI, USA). Amino acids are described with the N1 numbering.

###### 

Primers used for NA and HA gene sequencing of A(H1N1)pdm09 viruses

  Primer[a](#irv12132-note-0002){ref-type="fn"}   Sequence (5′--3′)
  ----------------------------------------------- --------------------------
  Primers for NA                                  
  N1‐F1                                           AGCAAAAGCAGGAGTTCAAAATGA
  N1‐17‐35F                                       AGATAATAACCATTGGTTC
  N1‐290‐307F                                     GGGCTATATACAGTAAAG
  N1‐434‐416R                                     GAATGTTTGTCATTTAGCA
  N1‐548‐532R                                     GCACTTGCTGACCAAGC
  N1‐676‐694F                                     ACACAAGAGTCTGAATGTG
  N1‐941‐959F                                     TAGGATACATATGCAGTGG
  N1‐959‐941R                                     CCACTGCATATGTATCCTA
  N1‐1111‐1130F                                   TTTGAGATGATTTGGGATCC
  N1‐1130‐1111R                                   GGATCCCAAATCATCTCAAA
  N1‐1394‐1375R                                   AATGGCAACTCAGCACCGTC
  N1‐R1                                           GTAGAAACAAGGAGTTTTTTGAAC
  Primers for HA1                                 
  H1HA1‐BEGIN                                     AGCAAAAGCAGGGGAAAATAA
  H1‐56‐76F                                       CATTATGTATAGGTTATCATG
  H1‐277‐296F                                     TGGTCCTACATTGTGGAAAC
  H1‐385‐366R                                     CAAATGATGACACTGAGCTC
  H1‐596‐578R                                     GGATGGTGAATGCCCCATA
  H1‐768‐788F                                     AATAACATTCGAAGCAACTGG
  H1‐1106‐1087R                                   TGATAACCGTACCATCCATC

Based on cRNA sequences of A/Narita/1/2009 virus.

Accession numbers for NA and HA genes are [EPI179482](EPI179482) and [EPI179438](EPI179438), respectively.
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NA inhibition assay {#irv12132-sec-0010}
-------------------

An NA inhibition assay was performed to determine the susceptibility of viruses to NA inhibitors. Four NA inhibitors, oseltamivir carboxylate (F. Hoffmann‐La Roche Ltd., Basel, Switzerland), zanamivir (GlaxoSmithKline, Stevenage, UK), peramivir (Shionogi & Co., Ltd., Osaka, Japan), and laninamivir (Daiichi Sankyo Co., Ltd., Tokyo, Japan) were kindly provided by the manufacturers. The susceptibility of viruses to NA inhibitors was determined by chemiluminescent enzyme inhibition assay with the NA‐Star Influenza Neuraminidase Inhibitor Resistance Detection kit (Applied Biosystems). Results were expressed as the drug concentrations required to inhibit NA activity by 50% (IC~50~). The IC~50~ values were calculated using MikroWin 2000 software (Mikrotek Laborsysteme GmbH, Overath, Germany) as previously described.[6](#irv12132-bib-0006){ref-type="ref"} The WHO expert working group on surveillance of influenza antiviral susceptibility has defined criteria of NA inhibitor susceptibility based on the fold change of IC~50~ values compared with reference IC~50~ values.[8](#irv12132-bib-0008){ref-type="ref"} For influenza A viruses, use of normal (\<10‐fold increase), reduced (10‐ to 100‐fold increase), and highly reduced (\>100‐fold increase) inhibition, and for influenza B viruses, the same criteria but using \<5‐fold, 5‐ to 50‐fold and \>50‐fold increases, is recommended.

Statistical analysis {#irv12132-sec-0011}
--------------------

Box‐and‐whisker plots were used to identify extreme IC~50~ values as previously described.[9](#irv12132-bib-0009){ref-type="ref"} The box contains 50% of the results, representing the middle two quartiles (25--75%). The length of the box represents the interquartile range (IQR). The whiskers extend to the largest and smallest values in the central part of the distribution before the region containing outliers is reached. The mild (between 1·5 and 3·0 IQR from the 25th and 75th percentiles) and the extreme (\>3·0 IQR from the 25th and 75th percentiles) outliers are defined. Differences between groups were evaluated by chi‐square test. *P* values less than 0·05 were considered statistically significant.

Phylogenetic analysis {#irv12132-sec-0012}
---------------------

Nucleotide sequences of the full‐length NA gene and the HA1 domain of the HA gene were subjected to phylogenetic analysis. Multiple alignments and phylogenetic trees were constructed using the MEGA 5·0 software.[10](#irv12132-bib-0010){ref-type="ref"} The phylo‐genetic trees were obtained by the neighbor‐joining method with bootstrap analysis of 1000 replicates. Accession numbers for the sequences used in the trees are shown in Table [2](#irv12132-tbl-0002){ref-type="table-wrap"}.

###### 

Accession numbers for the sequences used in the phylogenetic trees

  Viral isolates_HA sequence_NA sequence
  -------------------------------------------
  A/AICHI/1019/2009_EPI232919\_‐
  A/AICHI/1121/2009_EPI233018\_‐
  A/AOMORI/18/2010_EPI272597_EPI272596
  A/AOMORI/3/2010_EPI272391_EPI272390
  A/CHIBA‐C/41/2010_EPI277581_EPI277580
  A/CHIBA/1067/2009_EPI278741_EPI278742
  A/CHIBA/12/2010_EPI295380_EPI295379
  A/EHIME/65/2009_EPI272576_EPI272575
  A/FUKUI/67/2011_EPI321458_EPI321457
  A/FUKUI/72/2011_EPI329091_EPI334477
  A/FUKUOKA‐C/34/2010_EPI272600_EPI272599
  A/FUKUOKA/1/2010_EPI248527_EPI248526
  A/GIFU/21/2011_EPI321474_EPI321473
  A/HAMAMATU‐C/7/2011_EPI321452\_‐
  A/HIROSHIMA‐C/26/2010_EPI272568_EPI272567
  A/HIROSHIMA/17/2012_EPI378229_EPI378228
  A/HIROSHIMA/18/2012_EPI378231_EPI378230
  A/HIROSHIMA/49/2011_EPI316263_EPI318152
  A/HIROSHIMA/66/2011_EPI321439_EPI329139
  A/HOKKAIDO/12/2011_EPI316280_EPI318171
  A/HOKKAIDO/93/2011_EPI321482_EPI321481
  A/HYOGO/3017/2010_EPI278711_EPI278710
  A/HYOGO/4012/2011_EPI320241_EPI320240
  A/IBARAKI/103/2011_EPI321464_EPI321463
  A/IBARAKI/115/2010_EPI277575_EPI277574
  A/ISHIKAWA/566/2009_EPI240597\_‐
  A/ISHIKAWA/70/2011_EPI321456_EPI321455
  A/IWATE/1030/2010_EPI272571_EPI272570
  A/KANAGAWA/75/2011_EPI329105_EPI329104
  A/KAWASAKI/122/2011_EPI336870_EPI336869
  A/KOBE/181/2010_EPI278693_EPI278692
  A/KUMAMOTO‐C/39/2011_EPI378237_EPI378236
  A/KUMAMOTO/2/2010_EPI272399_EPI272398
  A/KUMAMOTO/20/2010_EPI272582_EPI272581
  A/MIYAGI/32/2011_EPI329100_EPI338384
  A/MIYAZAKI/40/2011_EPI321462_EPI321461
  A/NAGANO‐C/152/2009_EPI240602\_‐
  A/NAGANO‐C/21/2012_EPI378227_EPI378226
  A/NAGANO‐C/82/2009_EPI230097_EPI230096
  A/NAGANO/2289/2011_EPI329071_EPI334475
  A/NAGOYA/1013/2010_EPI276934_EPI276933
  A/NARA/39/2010_EPI291745_EPI291744
  A/NARA/59/2011_EPI321490_EPI321489
  A/NARITA/1/2009_EPI179438_EPI179482
  A/NIIGATA‐C/186/2009_EPI272415_EPI272414
  A/NIIGATA/1813/2009_EPI272411_EPI272410
  A/NIIGATA/529/2010_EPI272609_EPI272608
  A/OITA/126/2009_EPI226296_EPI226295
  A/OITA/49/2010_EPI272588_EPI272587
  A/OITA/57/2010_EPI272612_EPI272611
  A/OKINAWA/40/2011_EPI320274_EPI320273
  A/OSAKA‐C/20/2010_EPI272585_EPI272584
  A/OSAKA‐C/2004/2011_EPI329081_EPI329080
  A/OSAKA/52/2011_EPI320269_EPI320268
  A/OSAKA/58/2010_EPI272618_EPI272617
  A/OSAKA/60/2010_EPI279612_EPI286663
  A/SAITAMA/160/2011_EPI329078_EPI329077
  A/SAITAMA/289/2011_EPI329107_EPI334515
  A/SAITAMA/319/2011_EPI348493_EPI348492
  A/SAITAMA/80/2012_EPI378239_EPI378238
  A/SAPPORO/190/2009_EPI230125_EPI230124
  A/SAPPORO/163/2011_EPI329106_EPI334513
  A/SAPPORO/31/2010_EPI254533_EPI254532
  A/SAPPORO/4/2012_EPI356998_EPI356997
  A/Sendai‐H/41/2010_EPI240607\_‐
  A/SENDAI/151/2009_EPI287187_EPI287186
  A/SHIMANE/1062/2009_EPI234600\_‐
  A/SHIMANE/164/2011_EPI329051_EPI329050
  A/SHIZUOKA‐C/38/2010_EPI272421\_‐
  A/SHIZUOKA/59/2012_EPI378233_EPI378232
  A/TOCHIGI/34/2011_EPI329049_EPI329048
  A/TOCHIGI/87/2010_EPI272627_EPI272626
  A/TOKUSHIMA/2/2009_EPI214013_EPI214014
  A/TOKYO/11203/2011_EPI329098_EPI329097
  A/TOKYO/91256/2009_EPI248546_EPI248545
  A/TOTTORI/225/2009_EPI248548_EPI248547
  A/WAKAYAMA‐C/19/2010_EPI276936_EPI276935
  A/WAKAYAMA/23/2011_EPI316261_EPI318149
  A/WAKAYAMA/34/2010_EPI272591_EPI272590
  A/WAKAYAMA/8/2011_EPI320251_EPI320250
  A/YAMAGATA/206/2011_EPI333154_EPI333153
  A/YAMAGATA/752/2009_EPI241773\_‐
  A/YAMAGUCHI/23/2010_EPI272639_EPI272638
  A/YOKOHAMA/1538/2009_EPI244285_EPI244284
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Results {#irv12132-sec-0013}
=======

Detection of A(H1N1)pdm09 viruses with the H275Y substitution {#irv12132-sec-0014}
-------------------------------------------------------------

During the 2008--2009 through the 2011--2012 influenza seasons, 38 292 cases of A(H1N1)pdm09 virus isolation/detection were reported in Japan (Figure [1](#irv12132-fig-0001){ref-type="fig"}A). We screened 12,026 isolates by allelic discrimination and/or partial NA gene sequencing to detect the H275Y substitution (Figure [1](#irv12132-fig-0001){ref-type="fig"}B). During the pandemic period, 10 (0·5%) of 2,168 isolates in the 2008‐2009 season and 69 (1·1%) of 6,005 isolates in the 2009--2010 season possessed the H275Y substitution (Figure [1](#irv12132-fig-0001){ref-type="fig"}B,C). During the post‐pandemic period, 78 (2·0%) of 3844 isolates in the 2010--2011 season were H275Y mutants. In the 2011--2012 season, there were no outbreaks of the A(H1N1)pdm09 virus in Japan, and no H275Y mutant virus was detected from the sporadic cases of A(H1N1)pdm09 virus infection. The detection rates of H275Y mutant viruses increased from 1·0% during the pandemic period to 2·0% during the post‐pandemic period. Most H275Y mutant viruses were detected in sporadic cases, and there were no geographical clusters of mutant virus in Japan.

![Detection of A(H1N1)pdm09 viruses with the H275Y substitution during the 2008--2012 influenza seasons in Japan. (A) Monthly reports of A(H1N1)pdm09 virus isolation/detection by local public health institutes under the National Epidemiological Surveillance of Infectious Diseases. (B) Number of A(H1N1)pdm09 viruses tested in this study. (C) Number of A(H1N1)pdm09 viruses with the H275Y substitution. Closed bars relate to the left *y*‐axis and open bars to the right *y*‐axis.](IRV-7-1390-g002){#irv12132-fig-0001}

Susceptibility of A(H1N1)pdm09 viruses with the H275Y substitution to NA inhibitors {#irv12132-sec-0015}
-----------------------------------------------------------------------------------

We analyzed 155 isolates in the 2008--2009 season, 685 isolates in the 2009--2010 season, 249 isolates in the 2010--2011 season, and eight isolates in the 2011--2012 season by the NA inhibition assay. The IC~50~ values of A(H1N1)pdm09 viruses with the H275Y substitution to NA inhibitors are shown in Figure [2](#irv12132-fig-0002){ref-type="fig"}. In the 2008--2009 season, susceptibility of viruses to oseltamivir and zanamivir was analyzed (Figure [2](#irv12132-fig-0002){ref-type="fig"}A). Peramivir was approved in Japan in January 2010 and was included in the NA inhibition assay for isolates collected from the 2009‐2010 season and later seasons (Figure [2](#irv12132-fig-0002){ref-type="fig"}B). Laninamivir was licensed in Japan in October 2010 and was included in the NA inhibition assay for isolates collected from the 2010‐2011 season and the 2011--2012 season (Figure [2](#irv12132-fig-0002){ref-type="fig"}C). H275Y mutant viruses from throughout the pandemic and post‐pandemic periods showed about 400‐ and 140‐fold increased IC~50~ values to oseltamivir and peramivir, respectively, compared with 275H. However, the IC~50~ values of H275Y mutants to zanamivir and laninamivir were comparable to those of viruses with 275H. These results indicate that the H275Y mutant viruses exhibit resistance to both oseltamivir and peramivir, but are sensitive to zanamivir and laninamivir. Moreover, there was no significant difference in the IC~50~ values to oseltamivir and peramivir among H275Y mutant viruses isolated in pandemic and post‐pandemic periods.

![Susceptibility of A(H1N1)pdm09 viruses with the H275Y substitution to NA inhibitors. IC ~50~ values of A(H1N1)pdm09 viruses to oseltamivir, zanamivir, peramivir, and laninamivir were determined by NA inhibition assay. Viruses were from the 2008--2009 (A), the 2009--2010 (B), and the 2010--2011 (C) influenza seasons. Box‐and‐whisker plots of IC ~50~ values are shown. Numbers on top of each box‐and‐whisker plot indicate the mean IC ~50~ value ± 1 standard deviation.](IRV-7-1390-g003){#irv12132-fig-0002}

Age distribution of patients with oseltamivir‐ and peramivir‐resistant A(H1N1)pdm09 viruses {#irv12132-sec-0016}
-------------------------------------------------------------------------------------------

The age distributions of patients infected with A(H1N1)pdm09 viruses are shown in Figure [3](#irv12132-fig-0003){ref-type="fig"}. The total number of infected patients peaked at 10--19 years of age in the 2008--2009 season (Figure [3](#irv12132-fig-0003){ref-type="fig"}A). During the 2009--2010 and 2010--2011 seasons, the total number of infected patients peaked at 0--9 years of age. The percentages of patients aged 0‐9 years in the total number of patients with oseltamivir‐ and peramivir‐resistant viruses were 50% in the 2008--2009 season, 65% in the 2009--2010 season, and 49% in the 2010--2011 season (Figure [3](#irv12132-fig-0003){ref-type="fig"}B). These results indicate that the majority of resistant viruses are detected in infants and young children. Moreover, the percentage of individuals aged 10--19 years and 50--59 to 60--69 years with resistant viruses increased in the post‐pandemic period rather than in the pandemic period.

![Age distribution of patients with oseltamivir‐ and peramivir‐resistant A(H1N1)pdm09 viruses. Age distribution of patients during the 2008--2009, the 2009--2010, and the 2010--2011 influenza seasons. (A) The proportion of patients infected with A(H1N1)pdm09 viruses. (B) The proportion of patients with resistant viruses.](IRV-7-1390-g001){#irv12132-fig-0003}

Prescription history of patients with oseltamivir‐ and peramivir‐resistant A(H1N1)pdm09 viruses {#irv12132-sec-0017}
-----------------------------------------------------------------------------------------------

The prescription history of patients with H275Y mutant viruses is shown in Table [3](#irv12132-tbl-0003){ref-type="table-wrap"}. The majority of H275Y mutant viruses was detected from the patients during treatment or prevention with oseltamivir (80% and 81% during the pandemic periods, 2008--2009 and 2009--2010 seasons, respectively, and 42% during the post‐pandemic period, 2010--2011 season). Eight percent of the total H275Y mutants were detected from the patients that had been treated with peramivir in the 2010--2011 season. Noteworthily, 40% in the 2008--2009 season, 12% in the 2009--2010 season, and 18% in the 2010--2011 season of the total H275Y mutants were detected from the prophylactic use of oseltamivir with a half dose (75 mg once daily).

###### 

Prescription history of patients with A(H1N1)pdm09 viruses with the H275Y substitution

  Prescription history                                 2008--2009 season   2009--2010 season   2010--2011 season                      
  ---------------------------------------------------- ------------------- ------------------- ------------------- -------- --------- ---------
  Oseltamivir[a](#irv12132-note-0004){ref-type="fn"}   56 (4)              8 (4)               570 (9)             56 (8)   72 (16)   33 (14)
  Zanamivir[a](#irv12132-note-0004){ref-type="fn"}     27                  0                   91 (1)              0        24        1
  Peramivir                                            0                   0                   0                   0        14        6
  Laninamivir                                          0                   0                   0                   0        5         0
  Oseltamivir and peramivir                            0                   0                   0                   0        7         2
  Oseltamivir and zanamivir                            0                   0                   20                  2        0         0
  Peramivir and zanamivir                              0                   0                   0                   0        1         0
  No known exposure to drug                            888                 2                   1379                11       250       34
  Insufficient information                             1197                0                   3945                0        3471      2
  Total                                                2168                10                  6005                69       3844      78

Cases who received prophylaxis are shown in parentheses.
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Among the cases of H275Y mutant virus infections, the percentage of no known exposure to antiviral drugs significantly increased from 16% during the pandemic period to 44% during the post‐pandemic period (*P* \< 0·05), suggesting that human‐to‐human transmission cases of the resistant viruses had gradually increased. In fact, two clusters of resistant virus infection with suspected human‐to‐human transmission were independently observed. The first cluster occurred in a facility for handicapped individuals in eastern Japan in January--February 2011. In this cluster, resistant viruses with the H275Y mutation were detected in three patients who received prophylaxis with oseltamivir; 1 week later, the resistant viruses were detected in three patients who were not exposed to antivirals. The HA, NA, and matrix (M) genes of the six resistant viruses were sequenced and confirmed to possess the same amino acid sequences, implying that a single H275Y mutant virus circulated among the patients in the facility. The second cluster of cases occurred in a hospital in western Japan in February--March 2011. In this cluster, resistant viruses with the H275Y mutation were detected in three immunocompromised inpatients who had received prophylaxis with oseltamivir and was then later detected in a nurse. These four viruses possessed the same HA and NA amino acid sequences. However, there is no evidence of widespread outbreaks of the resistant viruses in the community, although the number of suspected cases of human‐to‐human transmission of drug‐resistant viruses increased.

Phylogenetic analyses of the NA and HA1 genes of A(H1N1)pdm09 viruses {#irv12132-sec-0018}
---------------------------------------------------------------------

Representative isolates from the 2008--2009 season through the 2011--2012 season were used for the phylogenetic analysis. Viruses isolated in the 2009--2010 (yellow), 2010--2011 (orange), and 2011--2012 (blue) seasons contained NA genes that belonged to the N248D clade (Figure [4](#irv12132-fig-0004){ref-type="fig"}A). The 2010--2011 and 2011--2012 isolates fell into the V241I and N369K subclades. Viruses isolated in the 2009--2010 (yellow), 2010--2011 (orange), and 2011--2012 (blue) seasons contained HA1 genes that fell into S203T clade (Figure [4](#irv12132-fig-0004){ref-type="fig"}B). The 2010--2011 and 2011--2012 isolates tended to fall into the S143G subclade. The H275Y mutant viruses did not form any certain clade in the NA and the HA1 phylogenetic tree.

![Phylogenetic trees of the A(H1N1)pdm09 virus NA and HA1 genes. Phylogenetic trees of NA (A) and HA1 (B) genes were constructed by the neighbor‐joining method with bootstrap values of 1000 replicates. Amino acid substitutions relative to the A/California/07/2009 virus are shown on the left side of the node. Bootstrap values are indicated only when greater than 50%. Viruses isolated in the 2008--2009, the 2009--2010, the 2010‐2011, and the 2011--2012 influenza seasons are colored in green, yellow, orange, and blue, respectively. The blue circles indicate the H275Y mutant viruses in the cases with no known exposure to antiviral drug. The H275Y mutant viruses in the cases associated with antiviral drug use are represented by red circles. The scale bar shows the nucleotide substitutions per site.](IRV-7-1390-g004){#irv12132-fig-0004}

Discussion {#irv12132-sec-0019}
==========

The highest frequency of antiviral drug use throughout the world has been recorded in Japan, ever since the NA inhibitors zanamivir and oseltamivir were licensed and covered by national health insurance in Japan in 2000 and 2001, respectively.[5](#irv12132-bib-0005){ref-type="ref"} Consequently, surveillance information on antiviral‐resistant viruses from Japan is valued by clinical and public health sectors throughout the world. We screened 12 026 A(H1N1)pdm09 viruses isolated in Japan from the 2008--2009 season through the 2011--2012 season and detected 157 (1·3%) resistant viruses with the H275Y substitution in the NA protein. These H275Y mutant viruses were confirmed to be resistant to both oseltamivir and peramivir, but sensitive to zanamivir and laninamivir, which is consistent with previous findings that oseltamivir‐resistant viruses exhibit cross‐resistance to peramivir.[11](#irv12132-bib-0011){ref-type="ref"}, [12](#irv12132-bib-0012){ref-type="ref"} The detection rates of the resistant viruses were 0·5% in the 2008--2009 season, 1·1% in the 2009--2010 season, and 2·0% in the 2010‐2011 season in Japan. These detection rates were similar to the rates detected by the surveillance of NA inhibitor‐resistant former seasonal A(H1N1) viruses collected in Japan during the 1999--2002,[9](#irv12132-bib-0009){ref-type="ref"} the 2003--2007,[5](#irv12132-bib-0005){ref-type="ref"} and the 2007--2008 seasons.[13](#irv12132-bib-0013){ref-type="ref"}

In our study of A(H1N1)pdm09 viruses, the proportion of patients with oseltamivir‐ and peramivir‐resistant viruses among those who were 0--9 years of age was high. The administration of oseltamivir to patients aged 10--19 years has been restricted by the Ministry of Health, Labour and Welfare of Japan, since 2007 due to reports of abnormal behavior after oseltamivir treatment. The percentages of patients aged 0--9 and 10--19 years in the total number of patients prescribed with NA inhibitors are 39·3 and 18·1% in the 2008--2009 season, 36·9 and 33·8% in the 2009--2010 season, and 37·8 and 19·3% in the 2010--2011 season, respectively. Our finding is consistent with the previous cumulative data from clinical trials that the incidence of oseltamivir‐resistant viruses was 0·32% in adults aged 18--65 years and 4·1% in children aged 1--12 years.[14](#irv12132-bib-0014){ref-type="ref"} The higher incidence of resistant viruses among children appears to be related to longer periods of viral shedding and higher levels of viral titers.[15](#irv12132-bib-0015){ref-type="ref"}

Based on clinical history information, resistant virus infections were predominantly associated with the therapeutic use of oseltamivir or peramivir. However, 12--40% of the total resistant viruses were detected from patients under prophylaxis of oseltamivir with a subtherapeutic dose (75 mg once daily), but not a therapeutic dose (75 mg twice daily) as observed in our previous study.[6](#irv12132-bib-0006){ref-type="ref"} Most resistant viruses from the prophylactic use emerged sporadically, although a suspected human‐to‐human transmission case from a patient under treatment to a patient under prophylaxis was observed. The emergence of resistant viruses in patients who received prophylaxis cannot be disregarded, so that the prophylactic use of antivirals is generally not recommended and should be followed by monitoring for emergence of resistant virus. In Japan, the Japanese Association for Infectious Diseases has recommended post‐exposure prophylaxis in hospitals and nursing homes, following the recommendations of the Advisory Committee on Immunization Practices, USA[16](#irv12132-bib-0016){ref-type="ref"}, and the Health Protection Agency, UK.[17](#irv12132-bib-0017){ref-type="ref"} Consequently, the emergence of antiviral‐resistant viruses from the prophylactic use should be paid particular attention.

Among the cases with resistant viruses, the percentage of no known exposure to antiviral drugs significantly increased from 16% during the pandemic period to 44% during the post‐pandemic period. A similar increase was observed in other continents.[18](#irv12132-bib-0018){ref-type="ref"}, [19](#irv12132-bib-0019){ref-type="ref"}, [20](#irv12132-bib-0020){ref-type="ref"}, [21](#irv12132-bib-0021){ref-type="ref"}, [22](#irv12132-bib-0022){ref-type="ref"} These observations may suggest that limited human‐to‐human transmission with H275Y mutant viruses has gradually increased in the post‐pandemic periods. We observed suspected human‐to‐human transmission in two independent in‐facility infection clusters that occurred in eastern and western Japan in 2011. The former cluster occurred in a facility for handicapped individuals. H275Y mutant viruses with the same HA, NA, and M amino acid sequences were initially detected in patients who received prophylaxis with oseltamivir; 1 week after these initial infections, infections were detected in individuals who did not receive treatment or prophylaxis with antiviral drugs. In this cluster of cases, it appears that a single H275Y mutant circulated inside the facility and was transmitted among the patients. The second cluster of cases occurred in a hospital. The H275Y mutant viruses were initially detected in immunocompromised inpatients who had received prophylaxis with oseltamivir and then in a nurse. These H275Y mutant viruses possessed the same HA and NA amino acid sequences, suggesting human‐to‐human transmission of the mutant virus. These two suspected clusters of human‐to‐human transmission did not spread beyond the residential facility or hospital to the outside community. However, the increasing number of H275Y mutant infections among those with no known exposure to antivirals is a warning that continued surveillance to monitor human‐to‐human transmission of NA inhibitor‐resistant viruses is necessary worldwide; this is especially true as we had seen that oseltamivir‐resistant former seasonal A(H1N1) viruses with the H275Y mutation, which emerged in Europe in the 2007--2008 season, spread globally within a year.[1](#irv12132-bib-0001){ref-type="ref"}

Some potentially permissive substitutions together with the H275Y mutation in the NA protein were reported for A(H1N1) viruses[3](#irv12132-bib-0003){ref-type="ref"}, [4](#irv12132-bib-0004){ref-type="ref"} and A(H1N1)pdm09 viruses.[20](#irv12132-bib-0020){ref-type="ref"}, [22](#irv12132-bib-0022){ref-type="ref"} In the case of A(H1N1) viruses, R222Q and V234M (N2 numbering) substitutions in NA restored the surface‐expressed NA activity,[3](#irv12132-bib-0003){ref-type="ref"} and these substitutions occurred before the global emergence of H275Y mutant viruses. Three substitutions (T82K, K141E, and R189K) in the HA protein promoted virus replication in the presence of the H275Y substitution in NA.[4](#irv12132-bib-0004){ref-type="ref"} In the case of A(H1N1)pdm09 viruses, three substitutions (V241I, N369K, and N386S) in the NA protein may offset the destabilizing effect of the H275Y substitution.[20](#irv12132-bib-0020){ref-type="ref"} In our study, the H275Y mutant viruses did not possess these permissive substitutions and did not form any certain clade in the NA and the HA1 phylogenetic trees (Figure [4](#irv12132-fig-0004){ref-type="fig"}A,B). However, oseltamivir‐resistant A(H1N1)pdm09 viruses detected in a cluster of community cases in Australia contained the potentially permissive mutations in NA.[20](#irv12132-bib-0020){ref-type="ref"} Therefore, sustained monitoring of the NA and HA gene sequences together with antiviral susceptibility assays is important to explore the possibility of human‐to‐human transmission of NA inhibitor‐resistant viruses.
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